Alkermes Plc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Alkermes Plc 公司

Alkermes plc 是一家总部位于爱尔兰的生物制药公司，致力于开发神经科学领域的药物。该公司拥有一系列用于治疗酒精依赖、阿片类药物依赖、精神分裂症和 I 型双相情感障碍的商业产品，以及一系列用于治疗神经系统疾病的临床和临床前候选药物。该公司专注于 LYBALVI、Aristada/Aristada INITIO 和 VIVITROL 等商业产品，并推进专注于神经系统疾病的管线项目的开发。LYBALVI 是一种每日一次的口服非典型抗精神病药物，用于治疗患有精神分裂症的成年人和患有 I 型双相情感障碍的成年人，作为维持性单一疗法或用于躁狂或混合发作的急性治疗，作为单一疗法或锂或丙戊酸的辅助疗法。Aristada 是一种缓释型肌肉注射混悬液，用于治疗精神分裂症。该公司在俄亥俄州威尔明顿设有一家制造工厂。

Alkermes Plc简介



公司代码ALKS

公司名称Alkermes Plc

上市日期Jul 16, 1991

CEOMr. Richard F. Pops

员工数量1800

证券类型Ordinary Share

年结日Jul 16

公司地址Connaught House

城市DUBLIN

上市交易所NASDAQ Global Select Consolidated

国家Ireland

邮编D04 C5Y6

电话35317728000

网址https://www.alkermes.com/

公司代码ALKS

上市日期Jul 16, 1991

CEOMr. Richard F. Pops

Alkermes Plc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

69.74K

-5.42%

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+26.46%

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

+12.23%

Ms. Nancy S. Lurker

Independent Director

10.71K

+131.91%

Dr. Nancy L. Snyderman, M.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

69.74K

-5.42%

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

VIVITROL

121.66M

31.14%

ARISTADA

101.30M

25.93%

LYBALVI

84.28M

21.57%

Royalty Revenue - VUMERITY

32.02M

8.20%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.32M

7.76%

其他

21.09M

5.40%

暂无数据

业务

地区

业务USD

名称

营收

占比

VIVITROL

121.66M

31.14%

ARISTADA

101.30M

25.93%

LYBALVI

84.28M

21.57%

Royalty Revenue - VUMERITY

32.02M

8.20%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.32M

7.76%

其他

21.09M

5.40%

股东统计

更新时间: 8月16日周六

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

14.37%

The Vanguard Group, Inc.

10.98%

T. Rowe Price Associates, Inc.

5.97%

State Street Investment Management (US)

4.97%

Baker Bros. Advisors LP

3.88%

其他

59.83%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

14.37%

The Vanguard Group, Inc.

10.98%

T. Rowe Price Associates, Inc.

5.97%

State Street Investment Management (US)

4.97%

Baker Bros. Advisors LP

3.88%

其他

59.83%

股东类型

持股股东

占比

Investment Advisor

53.57%

Investment Advisor/Hedge Fund

29.42%

Hedge Fund

14.45%

Research Firm

3.16%

Pension Fund

2.38%

Individual Investor

1.65%

Sovereign Wealth Fund

1.18%

Private Equity

0.61%

Bank and Trust

0.44%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

743

174.30M

105.56%

-28.06M

2025Q2

770

179.09M

108.49%

-26.85M

2025Q1

781

180.42M

109.41%

-27.12M

2024Q4

750

175.04M

107.61%

-39.68M

2024Q3

727

186.93M

115.42%

-33.14M

2024Q2

708

187.79M

113.20%

-24.77M

2024Q1

682

184.21M

108.96%

-28.40M

2023Q4

653

184.12M

110.36%

-5.13M

2023Q3

620

171.53M

102.92%

-4.71M

2023Q2

610

167.10M

100.38%

-17.86M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

23.73M

14.37%

-251.67K

-1.05%

Jun 30, 2025

The Vanguard Group, Inc.

18.45M

11.18%

+290.40K

+1.60%

Jun 30, 2025

T. Rowe Price Associates, Inc.

9.86M

5.97%

-1.76M

-15.13%

Jun 30, 2025

State Street Investment Management (US)

8.21M

4.97%

+185.59K

+2.31%

Jun 30, 2025

Baker Bros. Advisors LP

6.41M

3.88%

+1.93M

+42.99%

Jun 30, 2025

Renaissance Technologies LLC

5.81M

3.52%

+71.33K

+1.24%

Jun 30, 2025

RTW Investments L.P.

4.68M

2.84%

-2.20M

-31.99%

Jun 30, 2025

Geode Capital Management, L.L.C.

4.02M

2.44%

+83.86K

+2.13%

Jun 30, 2025

American Century Investment Management, Inc.

3.66M

2.22%

+191.55K

+5.53%

Jun 30, 2025

JP Morgan Asset Management

3.95M

2.39%

-179.85K

-4.36%

Jun 30, 2025

持股ETF



更新时间: 11月6日周四

机构名称

占比

AdvisorShares Psychedelics ETF

5.6%

iShares Neuroscience and Healthcare ETF

4.16%

Invesco S&P SmallCap Health Care ETF

3.15%

First Trust NYSE Arca Biotechnology Index Fund

3.08%

ALPS Medical Breakthroughs ETF

2.88%

Knowledge Leaders Developed World ETF

1.7%

Abacus FCF International Leaders ETF

1.46%

Langar Global HealthTech ETF

1.46%

SPDR S&P Biotech ETF

1.39%

Invesco S&P SmallCap Quality ETF

1.33%

AdvisorShares Psychedelics ETF

占比5.6%

iShares Neuroscience and Healthcare ETF

占比4.16%

Invesco S&P SmallCap Health Care ETF

占比3.15%

First Trust NYSE Arca Biotechnology Index Fund

占比3.08%

ALPS Medical Breakthroughs ETF

占比2.88%

Knowledge Leaders Developed World ETF

占比1.7%

Abacus FCF International Leaders ETF

占比1.46%

Langar Global HealthTech ETF

占比1.46%

SPDR S&P Biotech ETF

占比1.39%

Invesco S&P SmallCap Quality ETF

占比1.33%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据